Pannex Therapeutics is a New York biotechnology company developing small-molecule therapies that block Pannexin 1 channels, initially for chronic neuropathic pain and triple-negative breast cancer. Founded by Panx1 research leader David Bravo and backed by a team with decades of biopharmaceutical drug-development experience, the company has built a patent-protected discovery platform with hundreds of rationally designed blockers. Its work aims to address shared neuroinflammatory and immune-signaling mechanisms across neurological disease and cancer.
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
P2D BioscienceP2D Bioscience is a specialty pharmaceutical company developing drug candidates for inflammatory disorders of the central nervous system, with a pipeline aimed at frontotemporal dementia, Alzheimer’s disease and ADHD. Its approach combines targeted phenotypic screening with transgenic preclinical models, while its management brings deep experience in neuroscience, toxicology and early-stage drug development. The company advances candidates through preclinical and early clinical studies before seeking partners for later development and commercialization.CINCINNATI, OH
BeyondSpringFounded in 2010, BeyondSpring is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, centered on its investigational lead asset Plinabulin. The Florham Park company is advancing Plinabulin as a GEF-H1 agonist that promotes dendritic-cell maturation and may help re-sensitize tumors after checkpoint-inhibitor treatment while reducing chemotherapy-induced neutropenia. Its development program has treated more than 700 cancer patients and includes the confirmatory DUBLIN-4 Phase 3 program in non-small-cell lung cancer.NEW YORK, NY